# US 2015/0148427 A1 · Modified release formulations of memantine oral dosage forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148427 A1
- Document ID: US20150148427A1
- Status: Published application
- Kind: A1
- Application number: 14/607,526
- Filed: 2015-01-28
- Published: 2015-05-28
- Earliest claimed: 2004-06-17
- Assignees: Forest Laboratories Holdings Limited
- Applicants: Forest Laboratories Holdings Ltd.
- Inventors: Suneel K. RASTOGI; Niranjan RAO; Antonia PERICLOU; Wattanaporn ABRAMOWITZ; Mahendra G. DEDHIYA; Shashank MAHASHABDE
- Web page: https://patentgrep.com/patent/US20150148427A1

## CPC

- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

## Claims

### Claim 1

A modified release solid oral dosage form comprising:
(a) at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and
(b) a pharmaceutically acceptable polymeric carrier substantially contributing to the modification of the release of said active ingredient,
said dosage form sustaining release of said therapeutically active agent from about 4 hours to about 24 hours following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

### Claim 2 (depends on 1)

The modified release solid oral dosage form according to claim 1, wherein said active ingredient is memantine hydrochloride.

### Claim 3 (depends on 1)

The modified release solid oral dosage form according to claim 1, wherein the dissolution rate of more than about 80% is achieved after about 12 hours.

### Claim 4 (depends on 3)

The modified release solid oral dosage form of claim 3, comprising the active ingredient in an amount within the range of from about 1.0% w/w to about 20% w/w.

### Claim 5 (depends on 1)

The modified release solid oral dosage form according to claim 1, wherein the dissolution rate of more than about 80% is achieved after about 6 hours.

### Claim 6 (depends on 5)

The modified release solid oral dosage form of claim 5, wherein the active ingredient is present in amounts ranging from about 1.0% w/w to about 35% w/w.

### Claim 7 (depends on 1)

The modified release solid oral dosage form of claim 1, wherein the polymeric carrier is a polymeric matrix.

### Claim 8 (depends on 7)

The modified release solid oral dosage form of claim 7, wherein the polymeric matrix is a swellable matrix and comprises hydroxypropyl methylcellulose.

### Claim 9 (depends on 8)

The modified release solid oral dosage form of claim 8, wherein the dissolution rate of more than about 80% is achieved after about 12 hours, and wherein the hydroxypropyl methylcellulose is present in amounts from about 50% w/w to about 80% w/w.

### Claim 10 (depends on 8)

The modified release solid oral dosage form of claim 8, wherein the dissolution rate of more than about 80% is achieved after about 6 hours, and wherein the hydroxypropyl methylcellulose is present in amounts from about 20% w/w to about 70% w/w.

### Claim 11 (depends on 1)

The modified release solid oral dosage form of claim 1, further comprising a filler.

### Claim 12 (depends on 11)

The modified release solid oral dosage form of claim 11, wherein the filler is lactose monohydrate.

### Claim 13 (depends on 12)

The modified release solid oral dosage form of claim 12, wherein the dissolution rate of more than about 80% is achieved after about 12 hours, and the lactose monohydrate is present in an amount from about 5% w/w to about 50% w/w.

### Claim 14 (depends on 12)

The modified release solid oral dosage form of claim 12, wherein the dissolution rate of more than about 80% is achieved after about 6 hours, and the lactose monohydrate is present in amounts from about 5% w/w to about 75% w/w.

### Claim 15 (depends on 11)

The modified release solid oral dosage form of claim 11, wherein the filler is microcrystalline cellulose.

### Claim 16 (depends on 15)

The modified release solid oral dosage form of claim 15, wherein the microcrystalline cellulose is present in an amount from about 5% w/w to about 80% w/w.

### Claim 17 (depends on 11)

The modified release solid oral dosage form of claim 11, wherein the filler is dicalcium phosphate.

### Claim 18 (depends on 17)

The modified release solid oral dosage form of claim 17, wherein the dicalcium phosphate is present in an amount from about 7% w/w to about 40% w/w.

### Claim 19 (depends on 1)

The modified release solid oral dosage form of claim 1, further comprising a lubricant.

### Claim 20 (depends on 19)

The modified release solid oral dosage form of claim 19, wherein the lubricant is magnesium stearate.

### Claim 21 (depends on 20)

The modified release solid oral dosage form of claim 20, wherein the dissolution rate of more than about 80% is achieved after about 12 hours, and wherein the magnesium stearate is present in an amount within the range from about 0.8% w/w to about 1.2% w/w.

### Claim 22 (depends on 20)

The modified release solid oral dosage form of claim 20, wherein the dissolution rate of more than about 80% is achieved after about 6 hours, and wherein the magnesium stearate is present in an amount within the range from about 0.4% w/w to about 0.6% w/w.

### Claim 23 (depends on 1)

The modified release solid oral dosage form of claim 1, further comprising one or more components selected from the group consisting of carriers, excipients, anti-adherants, fillers, stabilizing agents, binders, colorants, glidants, and lubricants.

### Claim 24

A modified release solid oral dosage form, comprising
(a) between about 2.5% w/w and about 20.0% w/w of memantine hydrochloride;
(b) between about 68% w/w and about 77% w/w of hydroxypropyl methyl cellulose;
(c) between about 6.9% w/w and about 15% w/w of lactose monohydrate;
(d) between about 0.8% w/w and about 1.3% w/w of fumed silica;
(e) between about 3.0% w/w and about 5.0% w/w of talc; and
(f) between about 0.9% w/w and about 1.1% w/w of magnesium stearate;
wherein the dissolution rate of memantine hydrochloride of more than about 80% is achieved after about 12 hours.

### Claim 25

A modified release solid oral dosage form, comprising:
(a) between about 5% w/w and about 35% w/w of memantine hydrochloride;
(b) between about 54% w/w and about 65% w/w of hydroxypropyl methyl cellulose;
(c) between about 7% w/w and about 24% w/w of lactose monohydrate;
(d) between about 0.8% w/w and about 1.3% w/w of fumed silica;
(e) between about 3.0% w/w and about 5.0% w/w of talc; and
(f) between about 0.4% w/w and about 0.6% w/w of magnesium stearate;
wherein the dissolution rate of memantine hydrochloride of more than about 80% is achieved after about 6 hours.

### Claim 26

A modified release solid oral dosage form, comprising:
(a) between about 5% w/w and about 35% w/w of memantine hydrochloride;
(b) between about 54% w/w and about 65% w/w of hydroxypropyl methyl cellulose;
(c) between about 7% w/w and 40% w/w of microcrystalline cellulose;
(d) between about 0.8% w/w and about 1.3% w/w of fumed silica;
(e) between about 3.0% w/w and about 5.0% w/w of talc; and
(f) between about 0.4% w/w and about 0.6% w/w of magnesium stearate;
wherein the dissolution rate of memantine hydrochloride of more than about 80% is achieved after about 6 hours.

### Claim 27

A modified release solid oral dosage form, comprising:
(a) between about 5% w/w and about 35% w/w of memantine hydrochloride;
(b) between about 54% w/w and about 65% w/w of hydroxypropyl methyl cellulose;
(c) between about 7% w/w and 40% w/w of dicalcium phosphate;
(d) between about 0.8% w/w and about 1.3% w/w of fumed silica;
(e) between about 3.0% w/w and about 5.0% w/w of talc; and
(f) between about 0.4% w/w and about 0.6% w/w of magnesium stearate;
wherein the dissolution rate of memantine hydrochloride of more than about 80% is achieved after about 6 hours.

### Claim 28 (depends on 24, 25, 26, 27)

The modified release solid oral dosage form of one of claims 24-27 wherein said modified release solid oral dosage form is a tablet.

### Claim 29 (depends on 1)

The modified release solid oral dosage form of claim 1, wherein the dissolution rate exhibited by said modified release solid oral dosage form after about 1 hour is at least about 10% and up to about 35%.

### Claim 30 (depends on 1)

The modified release solid oral dosage form of claim 1, wherein the dissolution rate exhibited by said modified release solid oral dosage form after about 2 to about 6 hours is at least about 30% and up to about 60%.

### Claim 31 (depends on 1)

The modified release solid oral dosage form of claim 1, wherein said modified release solid oral dosage form is administered once-a-day.

### Claim 32 (depends on 1)

A method for treating a disorder selected from the group consisting of mild, moderate and severe Alzheimer's dementia, and neuropathic pain, wherein the method comprises administering a modified release solid oral dosage form of claim 1.
